Pharmacological characterisation of erenumab, Aimovig, at two CGRP responsive receptors.

Published in: British journal of pharmacology (2023)

receptor. Its ability to antagonise CGRP activity at both receptors may be useful in better understanding the clinical profile of erenumab.

Keyphrases